Dr. Vinay Prasad, the highest regulator of US food and drug administration, resigned in less than three months in work after discussing the treatment of gene therapy Sarepta Therapeutics Inc.
“Dr. Prasad did not want to be a distraction of the great work of FDA in the administration of Trump and decided to return to California and spend more time with his family,” CNN quoted a spokesman for the US Department of Health and Human Services.
Who is Vinaj Prasad?
In May he was appointed hematologist and oncologist of Prasad, Head of the FDA Center for Biology Evaluation and Research and granted him the power of vaccines and biological drugs. Subsequently, he was also appointed FDA Medical and Scientific Director. As with several novelines of the Trump Administration, Prasad was a loud critic of government reaction and vaccination policy during the Covid-19 pandemic.
Resign Vinay Prasada
The report that quoted people who were aware of the development said that Praad resigned in the middle of pressure on the White House. In addition, Laura Loomer, a right -wing activist who is known to have close ties with Donald Trump, constantly criticized Pig. She publicly criticized him for days on her website and social media and called him a “progressive left -wing saboter” that “undermined FDA President Trump”.
Loomer called the previous posts and podcast episodes of Prasad’s social media, where she claimed to support liberal politicians and expressed the “contempt” of Trump.
Commissioner FDA Dr. Marty Makara, however, was defended a few days ago. In an interview with the Makara politician, Praad was “a perfect scientist… one of the greatest scientific minds of our generation.”
“We thank him for his service and for many important reforms he was able to achieve at the FDA in his time,” HHS spokesman said.
Controversy of the therapy of gene therapy Sarepta
Prasad took over its role on the FDA after years of open criticism of certain drug approval by the agency. In particular, he condemned the approval of Sarept’s spiritual muscle dystrophic drugs, evideidys, claiming that there was no sufficient evidence that would have effectively slowed or reversed the symptoms of this rare and deadly genetic state.
This month, the FDA asked Sarept to stop the shipment of the drug after the reported death of a young patient in Brazil. Just one day before Prazada left the agency unexpectedly reversed its decision and allowed Sarept to continue to transport in some patients.
Prasad faced criticism from former officials and vaccines after May’s internal notes showed that he had overtaken the FDA scientist on two new versions of Covid-19. The then director of CDDER criticized the wide use of these vaccines; In the end, the FDA approved them for older and immunocompromised individuals, but did not recommend them for younger Americans without basic health.
(Tagstotranslate) FDA
